Biotech Values

[DewDiligence]

DYAX addendum:

DYAX’s DX-88 is not only behind the Jerini/KOSP drug in timing, it also has caused the development of antibodies in several patients.

On DYAX’s recent CC, the CEO carried on about how these antibodies are non-neutralizing, but the simple truth is that antibody formation to a drug like this one is never a good thing.

The one bright spot for DYAX that I detected is that they may be close to inking a partnership for DX-88 in the CABG indication, where GENZ is not involved. But I probably wouldn’t buy the stock for this reason alone.